Fact CheckerSign in

NCT06043817RecruitingPhase 1/2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Source: ClinicalTrials.gov · Last updated 30 Oct 2026

Brief summary (registry, in English)

Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.

Status (registry)
Recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
345 (estimated)
First submitted
1 Sept 2023
Start date
26 Sept 2023
Primary completion date
1 Dec 2029
Lead sponsor
Pierre Fabre Medicament
Diseases
Lung cancer
NCT number
NCT06043817
EU CT number
2023-506759-51-00

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 345
  • From 26 Sept 2023 to the primary completion date, 1 Dec 2029
  • 41 sites in 10 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE Grade ≤1, except for alopecia and peripheral neuropathy

Other illness

  • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., could compromise the participant's well-being) or would prevent, limit, or confound the protocol-specified assessments

Lab values

  • Has a tumor that is known to harbor EGFR ex20ins p.H773\_V774insH variant, or any EGFR kinase domain activating mutation concurrent with either a T790M and/or C797S resistance mutations

Age

  • Has history (within ≤2 years before screening) of solid tumor or hematological malignancy that is histologically distinct from NSCLC

Other

  • Has symptomatic brain or spinal metastases

Who the study is looking for

  • Has histologically- or cytologically confirmed diagnosis of NSCLC Stage IIIB/C or IV not eligible for curative intent surgery or chemoradiation
  • Part 1: Tumor tissue EGFR or HER2 exon 20 insertion mutations confirmed by qualified local laboratories. Parts 2 and 3: EGFR/HER2 exon 20 insertion mutations confirmed by qualified local laboratories
  • Part 1: Has received all approved therapies for advanced or metastatic NSCLC or is ineligible. Part 2 and Part 3: Has received at least 1, but not more than 2, prior lines of approved treatment for advanced or metastatic NSCLC, 1 of which must be platinum-based chemotherapy unless contraindicated
  • Has documented tumor progression (based on radiological imaging)
  • Has new or recent tumor biopsy (collected at screening, if feasible) or archival tumor specimen collected in the past 10 years available for genomic profiling
  • Has at least one measurable tumor lesion per RECIST v1.1
  • Is ≥18 years of age at the time of signing the ICF
  • Has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (41)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Chris O'Brien Lifehouse Hospital
Coordinator of this site? Confirm its status
CamperdownAustraliaRecruiting
Charite Universitaetsmedizin Berlin KöR
Coordinator of this site? Confirm its status
BerlinGermanyRecruiting
Technische Universitaet Dresden
Coordinator of this site? Confirm its status
DresdenGermanyRecruiting
Goethe University Frankfurt
Coordinator of this site? Confirm its status
Frankfurt Am MainGermanyRecruiting
LMU Klinikum Muenchen AöR
Coordinator of this site? Confirm its status
MunichGermanyRecruiting
Hospital Universitari Vall d'Hebron
Coordinator of this site? Confirm its status
BarcelonaSpainRecruiting
Hospital San Pedro
Coordinator of this site? Confirm its status
LogroñoSpainRecruiting
Hospital Universitario Ramón y Cajal
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Hospital Universitario 12 de Octubre
Coordinator of this site? Confirm its status
MadridSpainRecruiting
Hospital Universitario Regional de Málaga
Coordinator of this site? Confirm its status
MálagaSpainRecruiting
University Hospital Virgen Del Rocio S.L.
Coordinator of this site? Confirm its status
SevillaSpainRecruiting
Institut Bergonie
Coordinator of this site? Confirm its status
BordeauxFranceRecruiting
Centre Hospitalier Universitaire de Lille
Coordinator of this site? Confirm its status
LilleFranceRecruiting
Centre Leon Berard
Coordinator of this site? Confirm its status
LyonFranceRecruiting
Centre Hospitalier Regional De Marseille
Coordinator of this site? Confirm its status
MarseilleFranceRecruiting
Institut De Cancerologie De L Ouest
Coordinator of this site? Confirm its status
Saint-Herblain CedexFranceRecruiting
Institut Universitaire Du Cancer Toulouse-Oncopole
Coordinator of this site? Confirm its status
Toulouse Cedex 9FranceRecruiting
Institut Gustave Roussy
Coordinator of this site? Confirm its status
VillejuifFranceRecruiting
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Coordinator of this site? Confirm its status
NaplesItalyNot yet recruiting
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Coordinator of this site? Confirm its status
OrbassanoItalyNot yet recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Coordinator of this site? Confirm its status
RomeItalyNot yet recruiting
Humanitas Mirasole S.p.A.
Coordinator of this site? Confirm its status
RozzanoItalyNot yet recruiting
Chungbuk National University Hospital
Coordinator of this site? Confirm its status
Cheongju-siSouth KoreaRecruiting
National Cancer Center
Coordinator of this site? Confirm its status
Goyang-siSouth KoreaRecruiting
CHA Bundang Medical Center, CHA University
Coordinator of this site? Confirm its status
Seongnam-siSouth KoreaRecruiting
Seoul National University Hospital
Coordinator of this site? Confirm its status
SeoulSouth KoreaRecruiting
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Coordinator of this site? Confirm its status
AmsterdamNetherlandsRecruiting
Uniwersyteckie Centrum Kliniczne
Coordinator of this site? Confirm its status
GdanskPolandNot yet recruiting
Instytut Centrum Zdrowia Matki Polki
Coordinator of this site? Confirm its status
LodzPolandNot yet recruiting
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
Coordinator of this site? Confirm its status
WarsawPolandNot yet recruiting
National Taiwan University Hospital
Coordinator of this site? Confirm its status
TaipeiTaiwanRecruiting
Taipei Veterans General Hospital
Coordinator of this site? Confirm its status
TaipeiTaiwanRecruiting
Levine Cancer Institute - Charlotte
Coordinator of this site? Confirm its status
CharlotteUnited StatesRecruiting
City of Hope
Coordinator of this site? Confirm its status
DuarteUnited StatesRecruiting
NEXT Virginia
Coordinator of this site? Confirm its status
FairfaxUnited StatesRecruiting
University of Texas - MD Anderson Cancer Center
Coordinator of this site? Confirm its status
HoustonUnited StatesRecruiting
City of Hope
Coordinator of this site? Confirm its status
Huntington BeachUnited StatesRecruiting
City of Hope
Coordinator of this site? Confirm its status
IrvineUnited StatesRecruiting
SCRI Oncology Partners - PPDS
Coordinator of this site? Confirm its status
NashvilleUnited StatesRecruiting
Thomas Jefferson University Research Facility
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesRecruiting
University of Utah - Huntsman Cancer Institute - PPDS
Coordinator of this site? Confirm its status
Salt Lake CityUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.